Nature Communications publication:A human endothelial cell-based recycling assay for screening of FcRn targeted molecules
In a study published in Nature Communications on February 12th, establishment of a novel in vitro cellular assay is reported, which can be used to gain in-depth insights into how antibodies and albumin variants are transported in and out of cells, and to predict how efficiently such molecules are rescued from intracellular degradation. The assay has been coined HERA and stands for human endothelial cell-based recycling assay.
The study is based on research conducted by scientists from the Laboratory of Adaptive Immunity and Homeostasis, headed by Jan Terje Andersen, at OUH and UiO, together with several international collaborators from Harvard Medical School, The Jackson Laboratory and Roche Pharma Research and Early Development in Munich.
Kyrre Emblem among the three research talents honoured by the Norwegian Research Council
One of The Norwegian Research Council's three new prizes for young outstanding researchers goes to Kyrre Eeg Emblem from the Department of Diagnostic Physics at the Division of Radiology and Nuclear Medicine. Each prize is 500.000 kroner and will be distributed on March 1st.
Kyrre Eeg Emblem's research will benefit cancer patients directly. Using MRI machines, he can predict how different therapies work on people with cancer. The goal is to understand how the treatment affects the disease, and thereby predict which patients respond to the cancer treatment.
Ole Jacob Elle appointed "Innovator of the Month" by "Helse Sør-Øst"
Ole Jacob Elle, head of the "Medical Robotics, visualisation and navigation" research group at The Intervention Centre at the Divsion of Emergencies and Critical Care has been selected as "Innovator of the Month" by the South-Eastern Norway Regional Health Authority (Helse Sør-Øst RHF). Elle's research activities and interests are presented in a popular science article (in Norwegian) entitled "Technology and health - hand in hand". He is fascinated by robots, holograms and navigation systems, and how these things can make everyday life in health care better.
Substantial grant from HELSEVEL to Jon Michael Gran
Jon Michael Gran, researcher at the Oslo Centre for Biostatistics and Epidemiology (OCBE), recently received a grant of 15 million NOK from the Research Council of Norway (HELSEVEL program). The title of the project is “Effects of workplace initiatives on sick leave and work participation - new statistical and causal models to utilise population registries”. The project will utilise large linked population-wide registry data in assessing the effects of the Norwegian Agreement on a More Inclusive Working Life (the IA Agreement) and the use of graded sick leave on long-term health related absence from work.
Leiv Arne Rosseland "Researcher of the Month" for January 2018
Leiv Arne Rosseland from the Division of Emergencies and Critical Care was appointed "Researcher of the Month" for January 2018 by the South-Eastern Norway Regional Health Authority (Helse Sør-Øst RHF). Rosseland works within the field of pain relief, especially related to obstretic anasthesia. He is also concerned that we use the good registry data that we have more actively than today. Rosseland's work is presented in a feature article published on the home page of Helse Sør-Øst.
Interdepartmental collaboration cuts drug costs on expensive antibodies for treating eye diseases
Since their introduction 12 years ago, intravitreal anti-vascular endothelial growth factor (VEGF) drugs have gradually become the standard of care for several prevalent and debilitating retinal eye diseases. The anti-VEGF treatment is given by an injection into the eye. In a ground-breaking project, clinicians, researchers and pharmacists at Oslo University Hospital (OUH) and University of Oslo (UiO) have collaborated to improve the safety, efficacy and economy of the anti-VEGF procedure, which in 2017 was performed about 23.000 times at OUH alone. The results are likely to impact practices across Norway and also internationally.
Prestigious grant to Tor Erik Rusten
As one of 24 PIs in Norway (all disciplines included), Tor Erik Rusten, who is group leader at Institute for Cancer Research and PI in Centre for Cancer Cell Reprogramming (CanCell), has been awarded a prestigious “Toppforsk” grant from the Research Council for the project “Tumor-Host Biology”.
Each of the 24 projects receive between 15 and 25 mill NOK. The grants are aimed at research communities that have the potential to become international leaders within their fields.
Two of the 24 selected projects are led by group leaders at the Institute for Cancer Research. The other is Karl-Erik Malmberg from the Department of Cancer Immunology.
OUH research seminar, Monday, February 5th, 2018, at 14:30 – 16:00New developments in gynecologic oncology
Welcome to the next Oslo University Hospital (OUH) research seminar entitled: New developments in gynecologic oncology
Time: Monday, February 5th, 2018, at 14:30 – 16:00 Place: Red Auditorium, Rikshospitalet, Sognsvannsveien 20, Oslo
Speakers: Annetine Staff, Kjersti Skipar, Ane Gerda Zahl Eriksson, Olesya Solheim and Kristina Lindemann.
Karl-Johan Malmberg interviewed by NRK on the potential of killer cell research in cancer treatment
Professor Karl-Johan Malmberg, head of the c at the Department of Cancer Immunology at the Institute for Cancer research, was recently interviewed on radio by the Norwegian Broadcasting Corporation (NRK) in connection with a news item on NRK radio and on their home page about recent research progress on the subject "how killer cells may overcome cancer" (entitled "Drepeceller kan ta knekken på kreft").
Therese Sørlie appointed "Scientist of the Month" by "Helse Sør-Øst"
The South-Eastern Norway Regional Health Authority (Helse Sør-Øst) aims to profile ongoing excellent research in the region by calling special attention to a "Scientist of the Month". This honour recently went to Therese Sørlie, department head at Department of Cancer Genetics at the Institute for Cancer Research and leader of the "Breast tumor initiation and progression" group. She is presented in a feature article (in Norwegian) entitled "Why does cancer become cancer?".
Rusten group research project on cell organisation and tumor growth highlighted by the Norwegian Cancer Society
The Norwegian Cancer Society awarded NOK 173.8 millions NOK to cancer research through the annual open announcement in 2017. They publish popular science articles about research projects supported by them regularly. The research of Tor Erik Rusten and his coworkers in from the Tumor-Host Biology research group at the Department of Molecular Cell Biology at the Institute for Cancer Research has recently been presented in an article (in Norwegian) entitled "Double agent in the body's cells makes tumors grow". Here it is explained how tumor cells lose orientation and grow uncontrollably when the "double agent" protein LKB1 leads the cells in the wrong direction under certain conditions.
Nominating outstanding scientists, closing date March 1st:Excellent Researcher Award and Early Career Award 2018
Oslo University Hospital announce research awards in the following categories for 2018:
Excellent Researcher Award (300.000 NOK)
Early Career Award (two prizes of 150.000 NOK)
The candidates must be employed by Oslo University Hospital or University of Oslo, and member of a research group at one of these institutions.
OUH research seminar, Monday, January 15th, 2018, at 14:30 – 16:00Genetics of cardiovascular diseases
Welcome to the next Oslo University Hospital (OUH) research seminar entitled: Genetics of cardiovascular diseases
Time: Monday, January 15th, 2018, at 14:30 – 16:00 Place: Red Auditorium, Rikshospitalet, Sognsvannsveien 20, Oslo
Speakers: Knut Erik Berge, Kristina Haugaa, Ida Gjervold Lunde, Øyvind H. Lie
Press releaseTillotts Pharma AG signs license agreement on antibody technology developed by OUS and UiO scientists
Inven2 AS (Inven2), a technology transfer and innovation company based in Oslo, Norway, and Tillotts Pharma AG (Tillotts), a wholly-owned subsidiary of Zeria Pharmaceutical Co., Ltd. (Zeria) announced on January 22nd that they have signed a license agreement granting Tillotts certain rights to a proprietary antibody backbone technology developed by Stian Foss, Inger Sandlie and Jan Terje Andersen at the University of Oslo and Oslo University Hospital (the Institutions). The partnership is governed by a license agreement, and also includes specific analyses conducted by the Institutions to aid in the lead candidate selection.
Cell therapy research presented in national newspaper VG
Research on immunotherapy conducted at the Department of Oncology is presented in a feature article in the popular national Norwegian newspaper Verdens Gang (VG) January 9th. The article focuses on recent progress in chimeric antigen receptor (CAR) T cell therapy. For two years, children with leukemia and adults with lymphoma has been treated through clinical studies. Now the project will be expanded with three new studies on lymphomas.
Preclinical drug screening identifies novel stratified treatment options according to the consensus molecular subtypes of colorectal cancer
In two recent publications (Eide PW et al. Sci Rep; Sveen A*, Bruun J* et al. Clin Cancer Res), scientists in the Lothe lab., Department of Molecular Oncology, have identified novel potential treatment strategies for colorectal cancer (CRC), guided by the consensus molecular subtypes (CMS). Combining algorithm development, for translation of CMS classification to preclinical models, with drug screening of classified cell lines and patient-derived xenografts (PDXs) in collaboration with the Finnish Institute for Molecular Medicine and Vall d´Hebron Institute of Oncology, a potential to overcome chemoresistance in the poor prognostic CMS4-mesenchymal group was identified by combination therapy with 5-fluorouracil (5-FU) and HSP90 inhibitors.
The discovery of TIGIT as a potential new target for immune checkpoint blockade is published in Clinical Cancer Research.
Biological advances have resulted in immunotherapeutic regimens that target co-inhibitory receptors such as PD-1 to reverse T-cell exhaustion and promote anti-tumor responses that eradicate human tumors. However, despite its success in many cancer types, a substantial number of patients do not respond to PD-1/PD-L1 blockade. This includes patients with the B-cell malignancy follicular lymphoma, suggesting that co-blockade of co-inhibitory receptors may be necessary to achieve optimal anti-tumor T-cell responses. In a study recently published in Clinical Cancer Research (journal impact factor 9.6), the authors demonstrate the power of using high dimensional flow cytometry analysis of follicular lymphoma tumors to identify new targets for checkpoint blockade.
Scientists from the Research Institute of Internal Medicine receive funding from ERA-Net
Professor Pål Aukrust has together with senior scientist dr. Arne Yndestad and professor Bente Halvorsen received ERA-NET funding on cardiovascular diseases (ERA-CVD). All three scientists are affiliated Research Institute of Internal Medicine at the Division of Surgery, Inflammatory Medicine and Transplantation (“KIT”), Oslo University Hospital and Institute of Clinical Medicine, University of Oslo.
The funding, amounting to 2.4 mill NOK over a period of three years, is based on a collaborative project with professor Joachim Schultze, Bonn, Germany, professor Michael Sieweki, Marseille, France, and professor Erik A Biessen, Maastricht, The Netherlands, who is heading the consortium. The project named AtheroMacHete (Atherosclerosis Macrophage Heterogeneity study) will particular focus on intra plaque macrophage heterogeneity in patients with atherosclerotic disorders and experimental model systems.
Oslo University Hospital has awarded 6 excellent articles for the first half-year of 2017
Six research groups were awarded for their excellent papers published during the first half-year of 2017 during a ceremony on December 16th. Each group received NOK 50.000 for use in further research. The prize winners gave short presentations of the main findings in their respective articles.
The six selected articles are of especially high quality, and they present important finding on both-short and long-term scales. The works reflect the good quality and the interdisciplinarity that characterises several research environments at Oslo University Hospital. The research is a fundamental condition for the institution to maintain and strenghten the quality in the patient treatment.
Per Steinar Halvorsen appointed "Innovator of the Month" by Helse Sør-Øst
Per Steinar Halvorsen, head of the "Clinical and experimental cardiovascular monitoring" research group at the Intervention Centre at the Division of Emergencies and Clinical Care, was appointed "Innovator of the Month" for the month of October by South-Eastern Norway Regional Health Authority (Helse Sør-Øst). His work is presented in an article (in Norwegian) entitled "Pacemaker of the future", published on the home page of Helse Sør-Øst.